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Abstract
Background: The c-Jun N-terminal kinase (JNK) signaling pathway plays an important role in neuronal pathophysiology.
Using JNK inhibitors, we examined involvement of the JNK pathway in cultured rat retinal ganglion cell (RGC) death and
in mouse retinal ischemia/reperfusion (I/R) injury of the visual axis. The in vitro effects of JNK inhibitors were
evaluated in cultured adult rat retinal cells enriched in RGCs. Retinal I/R was induced in C57BL/6J mice
through elevation of intraocular pressure to 120 mmHg for 60 min followed by reperfusion. SP600125 was
administered intraperitoneally once daily for 28 days. Phosphorylation of JNK and c-Jun in the retina was
examined by immunoblotting and immunohistochemistry. The thickness of retinal layers and cell numbers in
the ganglion cell layer (GCL) were examined using H&E stained retinal cross sections and spectral domain
optical coherence tomography (SD-OCT). Retinal function was measured by scotopic flash electroretinography
(ERG). Volumetric measurement of the superior colliculus (SC) as well as VGLUT2 and PSD95 expression were
studied.
Results: JNK inhibitors SP600125 and TAT-JNK-III, dose-dependently and significantly (p < 0.05) protected against
glutamate excitotoxicity and trophic factor withdrawal induced RGC death in culture. In the I/R model, phosphorylation
of JNK (pJNK) in the retina was significantly (p < 0.05) increased after injury. I/R injury significantly (p < 0.05) decreased
the thickness of retinal layers, including the whole retina, inner plexiform layer, and inner nuclear layer and cell
numbers in the GCL. Administration of SP600125 for 28 days protected against all these degenerative
morphological changes (p < 0.05). In addition, SP600125 significantly (p < 0.05) protected against I/R-induced
reduction in scotopic ERG b-wave amplitude at 3, 7, 14, 21 and 28 days after injury. SP600125 also protected
against the I/R-induced losses in volume and levels of synaptic markers in the SC. Moreover, the protective
effects of SP600125 in the retina and SC were also detected even with only 7 days (Days 1–7 after I/R) of
SP600125 treatment.
Conclusions: Our results demonstrate the important role the JNK pathway plays in retinal degeneration in
both in vitro and in vivo models and suggest that JNK inhibitors may be a useful therapeutic strategy for
neuroprotection of RGCs in the retina.
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Background
Activation of c-Jun N-terminal kinase (JNK) is frequently
observed in degenerative diseases in mammalian neuronal
system such as Alzheimer’s disease, Parkinson’s disease
and glaucoma [1–3]. As a member of the mitogen acti-
vated protein (MAP) kinase family, activation of JNK is
mediated by phosphorylation of various biological and
environmental stress factors [4, 5]. In particular, several
major inflammatory cascades, including oxidative stress,
inflammatory cytokines, pattern-recognition receptors,
and neurotransmitter receptors, activate the JNK signaling
pathway [6–9] followed by activation of downstream sig-
naling molecules such as c-Jun, ATF-2, ELK-1, and Stat3
[4, 5, 10]. These molecular events result in gene transcrip-
tion associated with various biological outcomes including
neuronal cell migration, cytoskeletal reorganization, and
cell death [11–15].
As part of the central nervous system, the visual system,
including retinal ganglion cells (RGC) and other neurons,
has been investigated to identify the influence of JNK
activation under various pathologic conditions. Tezel et al.
demonstrated that JNK signaling is associated with RGC
degeneration induced by tumor necrosis factor (TNF)
receptor after optic nerve (ON) injury [16]. Bessero et al.
reported that inhibition of JNK1 protected the retina from
NMDA-induced excitotoxicity [17]. In addition, combined
knockdown of Jnk2 and Jnk3 induced long-term protec-
tion of RGCs against axonal injury in mice [18]. Balaiya et
al. also observed increased phosphorylated JNK (pJNK) in
cultured RGCs exposed to hypoxic conditions [19]. More
recently, Welsbie et al. showed that knockdown of the
dual leucine zipper kinase, which is an upstream activator
of JNK, improved survival and function of RGCs [20].
Taken together, the JNK pathway appears to play a pivotal
role in RGC death under various insults and disease
conditions.
Ischemia and subsequent reperfusion elicits severe dam-
age in the visual system, leading to irreversible vision loss
in many ocular diseases including retinal vessel occlusion,
glaucoma, and diabetic retinopathy [21–23]. In particular,
ischemia/reperfusion (I/R) injury in the retina causes RGC
death, resulting in functional failure of transmitting visual
information to specific receptive fields in the brain
[24–26]. We previously reported that I/R damage in the
retina induced morphological and functional degener-
ation and RGC death that was associated with temporal
regulation of retinal gene expression [27]. In particular,
various gene clusters, especially those related to cell
death and inflammatory responses, were upregulated
post injury and directly associated with the JNK signaling
pathway in pathological stages of various diseases [28].
In this study, we evaluated the role JNK signaling
pathway plays in retinal degeneration and RGC death
using pharmacological JNK inhibitors in retinal cell
culture and mouse retinal I/R injury models. We first ex-
amined their protective effects against cell death in an
adult rat retinal cell culture. We further examined the
effect of JNK inhibition on I/R-induced changes in the
retina and SC. We found that JNK inhibition provided
total morphological and functional protection to RGCs.
Results
Protection of RGC death by JNK inhibitors
Several insults are known to induce cell death of purified
RGCs in vitro. Otori et al. showed that glutamate (5 to
500 μM) induced cell death of cultured rat RGCs in a
dose-dependent manner [29]. Withdrawal of trophic fac-
tors also induced cultured RGC death [30]. In addition,
TNFα from glia under ischemic conditions also induced
RGC death in a co-culture system [31]. Based on previ-
ous findings, we further investigated whether these RGC
death mechanisms are associated with JNK signaling.
Death of cultured RGCs was induced by treating cells
for 3 days with glutamate (100 μM), TNFα (10 ng/mL),
or TFW (trophic factor withdrawal) in the presence or
absence of various concentrations of the JNK inhibitors
SP600125 or TAT-JNKi-III. Cells were then fixed and
labeled with anti-Thy-1 antibody for RGC counting.
SP600125 treatment significantly (p < 0.05) enhanced RGC
survival in a dose-dependent manner against glutamate and
TFW-induced cell death (Fig. 1a and c), but did not protect
against TNFα-induced RGC death (Fig. 1e). Similarly, TAT-
JNKi-III also dose-dependently protected against RGC
death induced by glutamate and TFW, but not by TNFα
(Fig. 1b, d and f).
JNK activation induced by retinal I/R
JNK is activated via phosphorylation of threonine and
tyrosine residues located in the activation loop in the
carboxyl-terminus. Activated JNK subsequently phosphor-
ylates c-Jun [32, 33]. Therefore, we examined I/R-induced
phosphorylation of JNK and c-Jun in the whole retina at
various time points after injury using immunoblotting
analysis (Fig. 2). Retinal JNK phosphorylation was de-
tected at 0, 1, 6, 12, 24, and 72 h after I/R injury. As
previously reported, we also observed a basal level of
phosphorylated JNK at 0 h [34, 35]. JNK phosphoryl-
ation appeared to show a bi-phasic increase with an ini-
tial peak at 1 h (p < 0.05 vs. 0 h control) and a delayed
increase at 72 h after I/R injury (Fig. 2a). Interestingly,
c-Jun phosphorylation also closely correlated with the
JNK phosphorylation pattern (Fig. 2b).
In immunohistochemical analysis, basal level of JNK
phosphorylation was observed in the same location with
the RGC marker Tuj-1(magenta arrows) and OPL corre-
sponding with our immunoblotting results. I/R injury
induced drastic increase of JNK phosphorylation in Tuj-
1 positive RGCs at early post-I/R injury times (1 h and
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6 h) and detected in non-RGCs (white arrows) from
12 h to 72 h after I/R injury (Fig. 3). Notably, JNK phos-
phorylation was also observed in the INL from 6 h to
12 h after I/R injury, and in the IPL from 24 h to 72 h.
In addition, strong JNK phosphorylation was continu-
ously observed in OPL from 1 h to 72 h after I/R injury
(Fig. 3). Phosphorylated c-Jun was also detected in a very
similar manner to pJNK in I/R-injured retinas. Phos-
phorylated c-Jun was first observed in Tuj-1-positive
RGCs at 1 h (yellow arrows) after I/R injury, and the
presence of pc-Jun was continuously detected in both
RGCs and non-RGCs (white arrow) from 6 h to 72 h in
GCL after I/R injury (Fig. 4). As we also observed phos-
phorylation of pc-Jun in INL, we further stained phos-
phorylated c-Jun with bipolar cell (PKCα) and amacrine
cell (syntaxin) markers at 24 h after I/R injury. Interest-
ingly, phosphorylated JNK and c-Jun was not co-localized
with either bipolar or amacrine cells (white arrow) (Fig. 5).
Protection against I/R-induced retinal damage by
SP600125
Previously, it was shown that systemic administration of
SP600125 showed protection in neurodegenerative ani-
mal models such as focal brain ischemia, in which the
JNK signaling pathway are involved [36]. Therefore, we
administered SP600125 to mice in our model of retinal
I/R to determine potential protective effects of JNK in-
hibition based on our in vitro data. We preliminarily
verified in vivo inhibition of SP600125 against JNK and
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Fig. 1 JNK inhibitors protected against RGC death induced by glutamate (Glu) excitotoxicity and trophic factor withdrawal (TFW), but not by
tumor necrosis factor (TNF)-α. Cultured adult rat retinal cells were treated with the indicated concentration of JNK inhibitors SP600125 (a, c, e) or
TAT-JNKi-III (b, d, f) in the presence of the cytotoxic insults: 100 μM of Glu (a, b), TFW (c, d), or 10 ng/mL TNFα (e, f) for 3 days. Surviving cells
were fixed and labeled with anti-Thy-1 antibody and manually counted. Vehicle-treated (no insult) control group in each study defines 100 %.
Symbols represent mean ± SEM (n = 6–10). Asterisk indicates statistical difference (p < 0.05) between the JNK inhibitor-treated groups versus the
respective insult-only group by One-way ANOVA then Dunnett’s test
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(30 mg/kg) was administered intraperitoneally 2 h prior
to I/R injury followed by immunostaining analysis for
phosphorylated JNK and c-Jun after 24 h. As expected,
SP600125 administration decreased pc-Jun phosphoryl-
ation in both the GCL and INL (Additional file 1: Figure
S9). Three different doses of SP600125 (5, 15, 30 mg/kg)
or vehicle were administered intraperitoneally as de-
scribed above followed by once daily administration for
28 days after I/R injury. Histological measurement of
H&E stained retinas showed that I/R in the vehicle con-
trol group caused significant (p < 0.01) reduction of
retinal layer thickness, particularly in the IPL and INL
over 28 days (Fig. 6) as previously reported [27]. Import-
antly, administration of SP600125 at each of the three
doses completely prevented I/R-induced thinning of the
IPL and INL (Fig. 6). In addition to histology, we also
examined morphological changes of retina using SD-
OCT at various time points after I/R injury, with or with-
out SP600125 (15 mg/kg) treatment. I/R injury caused
progressive and significant (p < 0.05) thinning of the IPL
and INL, whereas SP600125 treatment ameliorated these
changes (Fig. 7). I/R-induced cell loss in the GCL was also
significantly attenuated by all three doses of SP600125
(Fig. 8). In addition, I/R injury significantly (p < 0.05)
reduced the scotopic ERG b-wave (Fig. 9b). The I/R-
mediated reduction in b-wave amplitudes were also
restored by SP600125 treatment (Fig. 9b).
Protection against I/R-induced degeneration of RGC
axons in the SC by SP600125
In the mouse visual system, approximately 95 % of RGC
axons project contralaterally [37], and at least 70 % of
RGCs project to the superficial layer of SC [38]. As shown
in Fig. 10, I/R injury caused a significant (p < 0.05) de-
crease (~20 %) in the superficial SC layer cross-sectional
area in the contralateral side of the I/R injury compared to
the ipsilateral side after 28 days. Importantly, administra-
tion of SP600125 (5, 15, 30 mg/kg) protected against this
I/R-induced SC neuron decrease. We also assessed the
synaptic terminal of RGC neurons in the SC superficial
layer by examining expression of the presynaptic marker
VGLUT2 (vesicular glutamate transporter 2). Furthermore,
we also quantified intensity of the postsynaptic marker
PSD95 to measure potential failure in post-synapses of
RGC neurons in the SC. I/R injury significantly (p < 0.05)
decreased expression of both VGLUT2 and PSD95 in the
contralateral SC in comparison to the ipsilateral side after
28 days. Decreased expression of these two markers were
attenuated by daily SP600125 administration for 28 days
(Fig. 11).
Fig. 2 Retinal I/R induced phosphorylation of JNK and c-Jun. Mouse retinas were collected at 1, 6, 12, 24, and 72 h post I/R injury. The 0 h control
represents the non-injured group. Western blotting analyses were conducted using total retinal proteins. a Representative images of phosphorylated
JNK (pJNK), total JNK, and loading control GAPDH as well as ratio of pJNK versus total JNK, analyzed by ImageJ. JNK phosphorylation was significantly
(p < 0.05) increased at 1 h after I/R injury by 2.87 (±1.87) fold compared to 0 h control. b Representative images of phosphorylated c-Jun (pc-Jun), total
c-Jun, and loading control GAPDH as well as ratio of pc-Jun versus total c-Jun analyzed by ImageJ. Bars represent mean ± SEM (n = 3). Asterisk indicates
statistical difference (p < 0.05) compared to the 0 h control group by One-way ANOVA then Dunnett’s test
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Protective effects in the retina and SC by only 7-day
treatment with SP600125
The above results demonstrated that daily treatment
with SP600125 for 28 days was protective against retinal
I/R-induced damage to the retina and SC. To assess
whether a shorter treatment period was also protective,
SP600125 (15 mg/kg) was administered daily for only
the first 7 days after I/R injury, and changes of the retina
and SC were monitored for 28 days. I/R-induced degener-
ation of the INL and IPL was completely ameliorated by
Fig. 3 Phosphorylated JNK was detected in retina after I/R injury. Frozen-sectioned (10 μm) retina samples from 0, 1, 6, 12, 24 and 72 h after I/R
injury were used for immunohistochemistry. Phosphorylated JNK was detected (green fluorescence). Tuj-1 immunofluorescence (red) was used
as RGC marker. DAPI staining (blue) represents cell nuclei for counter staining. The magenta arrows represent basal JNK phosphorylation in 0 h
retina. All yellow arrows represent phosphorylated JNK in RGC and white arrows represent non-RGC in GCL
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the 7-day administration of SP600125 as measured by SD-
OCT (Fig. 12). Similarly, 7-day treatment with SP600125
also prevented the loss of synapse markers VGLUT2 and
PSD95 in the SC, showing protection from RGC axon loss
(Fig. 13).
Discussion
In this report, we demonstrated that JNK inhibitors were
effective in protecting cultured adult rat RGCs from
cytotoxicity, and also against neurodegeneration in the
mouse of retinal I/R. In cultured adult rat retinal
Fig. 4 Phosphorylated c-Jun was detected in retina after I/R injury. Frozen-sectioned (10 μm) retina samples from 0, 1, 6, 12, 24 and 72 h after
I/R injury were used for immunohistochemistry. As with JNK, phosphorylated c-Jun was detected (green fluorescence). Tuj-1 immunofluorescence
(red) was used as RGC marker. DAPI staining (blue) represents cell nuclei for counter staining. All yellow arrows represent phosphorylated c-Jun in
RGC and white arrows represent non-RGC in GCL
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neurons, we confirmed previous findings that excitotoxi-
city, TFW, and TNFα result in loss of RGCs [30, 39].
We further showed that two selective JNK inhibitors,
SP600125 and TAT-JNKi-III, protected RGCs in a dose-
dependent manner against glutamate- and TFW-
induced cell death, but not TNFα cytotoxicity. These
findings agree with reports indicating the involvement of
JNK following NMDA excitotoxicity in the rat retina
[40, 41]. Furthermore, we established SP600125 as a
neuroprotective agent to neurons in the mouse retina
and SC following retinal I/R. To our knowledge, this is
the first study to validate the involvement of the JNK
pathway both in cytotoxic injury to cultured primary ret-
inal neurons, as well as in vivo following retinal I/R,
through multiple functional and morphological assess-
ments of these neural tissues.
We previously reported retinal I/R injury caused pro-
gressive morphological and functional degeneration in the
retina. We observed strong temporal correlation with vari-
ous pathological markers, including those related to proin-
flammatory response and cell death [27]. Here, we extend
those characterizations and further identify significant in-
creases in phosphorylation of JNK and its downstream
target c-Jun. Strong activation of JNK and c-Jun signaling
has been reported in animal models of CNS ischemia. In
transient forebrain ischemia induced by occlusion of the
common carotid artery, there were significant increases in
pJNK in hippocampal CA1 and CA3 neurons within
15 min of reperfusion [42–44]. Transient global ischemia
induced by cardiac arrest in mice and rats similarly led to
increased levels of active JNK in CA1 neurons [45, 46]. In
a murine model of middle cerebral artery occlusion, pJNK
was increased in the cerebral cortex and striatum [47–49].
Finally, in similar models of retinal I/R, active JNK signal-
ing has been identified throughout the neural layers of the
retina 24 h post ischemia [50–52].
Activation of JNK occurs in many neurodegenerative
diseases in addition to ischemic damage. Cerebral cortex
and hippocampal sections from Alzheimer’s disease pa-
tients have markedly increased pJNK staining co-localized
with neurofibrillary tangles [53]. In tissue samples from
Parkinson’s disease (PD) patients, pJNK staining was in
close proximity to Lewy bodies. Likewise, in the MPTP
mouse model of PD, there was significantly increased acti-
vation of the JNK pathway; and dual Jnk2/3 knockout
mice were protected against the neurodegenerative effects
of this toxin [2, 54]. Protective strategies aimed at the
reduction or removal of JNK through the use of mouse
genetics, viral vectors, and small molecule inhibitors
support the involvement of JNK signaling in multiple neu-
rodegenerative conditions.
The biphasic increase in pJNK and pc-Jun in our study
occurred over a 72 h time period. While our report
nicely showed the sustained expression of pJNK several
hours to days following reperfusion, it is interesting that
the most significant increases of pJNK and pc-Jun oc-
curred 1 h following reperfusion, which were observed
mainly in the Tuj-1 positive RGC cell population. Among
Fig. 5 Phosphorylated c-Jun was not co-localized with both bipolar cell and amacrine cells in retina after I/R injury. 10 μm frozen retinal sections
from 0, 1, 6, 12, 24 and 72 h after I/R injury were used to detect phosphorylated c-Jun (green fluorescence) in bipolar cells (a) and amacrine
cells (b). PKCα (a) or syntaxin (b) immunofluorescence (red) were used to identify bipolar cells or amacrine cells in INL. DAPI staining (blue)
represents cell nuclei for counter staining. All phosphorylated c-Jun in INL were indicated using white arrow (no co-localization) or yellow
arrow (co-localization) to show its location in INL with amacrine cells (a) and bipolar cells (b)
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the earliest responses to reperfusion of occluded blood
flow are influx of ions, excitatory neurotransmitter release,
and free radical formation [23]. Reactive oxygen species
(ROS) such as superoxide are potent activators of JNK sig-
naling, acting far upstream on the MAP3K ASK1. This
kinase-mediated activation by ROS facilitates apoptosis in
the mitochondria, as JNKs are known to activate caspases
and induce cytochrome c release [55, 56]. Thus, our ob-
served early activation of JNK signaling may be attributed
to the increase in free-radical production resulting from
reperfusion, and RGC may be the most susceptible cell
type to trigger JNK signaling by this microenvironmental
stress. Previously, Roth and colleagues showed increased
pJNK within 6 h after I/R [57]. This apparent discrepancy
in temporal retinal JNK activation may be explained by
slight differences between the models. Ross et al. used a
milder elevation of IOP to induce retinal ischemia in rats,
while our study was done in mice. Nonetheless, both stud-
ies indicate that JNK phosphorylation is widespread in
many cell types in the inner retina, including the GCL,
IPL and INL. In support, Schmid et al. showed that I/R in-
jury induced loss of amacrine cells, but not rod bipolar
cells in INL [58]. Together, these studies indicate that I/R
injury may trigger the activation of JNK pathway in associ-
ation with diverse microenvironmental changes in inner
retina and promote the cellular degeneration based on the
different susceptibility of each cells to specific initiating
factors.
Notably, we also observed that phosphorylated c-Jun
was not co-localized with amacrine cells and bipolar
cells, although we observed strong c-Jun phosphoryl-
ation in INL from 6 h to 72 h after I/R injury (Fig. 5). In
contrast, Gesslein et al. showed increased phosphory-
lated c-Jun signals in Müller cell bodies in the INL after
I/R injury [59]. In retinal I/R injury, Müller cell gliosis is
a major marker associated with their cellular changes
causing pathological progression [27]. Importantly, sev-
eral in vitro studies suggested that JNK pathway may be
involved in Müller cell activation related to proinflam-












































































Fig. 6 SP600125 protected against I/R-induced thinning of inner retinal layers. Three doses of SP600125 (5, 15, and 30 mg/kg) or vehicle were
administered intraperitoneally 2 h prior to retinal I/R injury followed by once daily dosing. After 28 days, histological changes in retinal thickness,
including whole retina (from NFL to ONL), IPL, INL and ONL were analyzed. Data represent mean ± SEM (n = 5) at each time point. The mean
thickness of the uninjured, vehicle-treated retinas was set as 100 %. In vehicle-treated group, I/R injury significantly reduced whole retina thickness
23.2 ± 5.7 % compared to non-injured contralateral retinas. In particular, IPL was reduced 38.0 ± 6.7 % and INL reduced 25.1 ± 7.4 %. No significant
layer change was observed in ONL. In contrast, no significant layer thickness reduction was observed from SP60025-administered groups at each
dose (5, 15 and 30 mg/kg). **: p < 0.01; NS: non-significant between contralateral control and I/R eyes by two-tailed, paired t-test
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Fig. 7 (See legend on next page.)
Kim et al. Molecular Neurodegeneration  (2016) 11:30 Page 9 of 19
uptake, which are also important I/R-induced molecular
stressors to determine the fate of retinal pathology
[60, 61]. Although further characterization is necessary,
our observations suggest that the cells co-localized with
phosphorylated c-Jun may be Müller cells based on their
locational polarity in the INL toward vitreous side [62]. In
addition, our data also suggest the diversity in the role of
the JNK pathway in different retinal cell types that may
result in different cellular fates such as programmed cell
death or inflammatory activation.
A number of strategies have been developed for inacti-
vation of the JNK pathway, either directly targeting one
or all of the JNK isoforms [18], the adapter protein JIP1
[63], or an upstream kinase such as MLK1/2/3 [64]. In-
hibition of JNK activation has been previously shown to
be an effective therapeutic strategy in vitro and in vivo.
Reduction of pJNK protected primary neuronal cultures
from TFW [65]. In animal studies, JNK inhibition pro-
duced a marked reduction in lesion size resulting from
brain ischemia and preserved neuronal health of affected
tissues, decreased the number TUNEL-positive cells fol-
lowing excitotoxicity, and rescued against retinal thin-
ning and cellular loss of RGCs [16–19, 41, 45, 65–67].
However, only a few studies have determined whether
JNK signaling is the critical pro-apoptotic mediator of
pathological structural and functional changes following
retinal I/R injury.
SP600125 is a widely used inhibitor for all three JNK
isoforms [68]. This compound showed significant protec-
tion in animal models of neurodegenerative disease [54],
cerebral ischemia [69, 70], and retinal excitotoxicity [41].
We evaluated the neuroprotective effect of SP600125 in
our model of retinal I/R injury. SP600125 protected
against thinning of the inner neural retinal layers and cel-
lular loss in the GCL. We used SD-OCT to temporally
and non-invasively follow morphological changes in the
retina of each mouse. Furthermore, we believe our study
to be the first to also show complete preservation of
retinal b-wave amplitude over a 28-day period after I/R
injury. Our findings of neuroprotection are in disagree-
ment with those previously published by Roth and col-
leagues, who reported a lack of protection by two different
JNK inhibitors including SP600125 [57]. This discrepancy
may be explained by the differences in dosing strategies.
Our study effectively protected the retina through two
different systemic dosing regimens that each required
daily administration following reperfusion in addition to a
dose given right before I/R injury. In contrast, Roth et al.
used a single post-ischemic intravitreal dose of SP600125.
A recent study showed JNK modulation and neuroprotec-
tion against retinal ischemia using crocetin, a carotenoid
derivative [52]. However, their assessments were made
only at 7 days post injury, and the long-term effectiveness
was not reported.
Pathological changes related to inner retinal injury are
not limited to just the retina because RGC axons form
synapses with neurons in the visual centers of the brain.
Degeneration of these brain neurons has been reported
after injury to the retina [71, 72]. In the mouse, 90–95 %
of axons in the optic nerve cross the optic chiasm and
progress toward the contralateral side of the brain [37].
(See figure on previous page.)
Fig. 7 SP600125 ameliorated I/R-induced progressive retina thinning. Retinal I/R injured mice were treated with SP600125 (15 mg/kg) or vehicle
for 28 days. SD-OCT was used to determine progressive changes in whole retinal layer (from NFL to ONL), and each of IPL, INL, and ONL. a Representative
images showing layer changes after 28 days post I/R injury. b Quantitative analyses of progressive changes of thickness of each layer at different time
points. Open symbols: I/R eyes; closed symbols: un-injured contralateral eyes. In vehicle-administered groups, whole retina thickness in I/R-injured eyes
were progressively decreased at 28 days of injury compared to contralateral non-injured eyes. These changes were mainly observed in inner retinal layers,
IPL and INL. In contrast, SP600125 administration inhibited I/R-induced layer reduction. Data are shown as mean and SEM (n = 4). Two-way
ANOVA analyses indicate that there were no significant time-dependent changes in all SP600125 groups, but significant differences were
detected between the control and I/R groups at certain time points (*: p < 0.05, **: p < 0.01, ***: p < 0.001 by Bonferroni’s post-hoc test).
(WRL: whole retina layer, NFL: nerve fiber layer, IPL: inner plexiform layer, INL: inner nuclear layer, ONL: outer nuclear layer)
Fig. 8 SP600125 protected against I/R-induced cell loss in the GCL.
Total cell numbers in the GCL were counted from retinas of vehicle
or SP600125-treated animals at 28 days after I/R injury. Non-injured
contralateral eyes were also analyzed for comparison. I/R injury induced
significant GCL cell loss (30.0 ± 5.6 %) compared to contralateral non-
injured eyes whereas SP600125 administration showed total protec-
tion. Data represent mean ± SEM (n= 5). *: p < 0.05; NS: non-significant
between contralateral control and I/R eyes by two-tailed, paired
Student’s t-test
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Among them, approximately 70 % of axon terminals are
localized in the superficial layer of the SC [38]. Damage
resulting from retinal ischemia leads to defects in an-
terograde transport and loss of innervation to the SC
[73], causing a significantly decreased visual evoked po-
tential response [74, 75]. Topical treatment with the
α2-adrenergic agonist brimonidine has been shown to
maintain innervation of the SC and protect against loss
of neuronal volume up to 3 months following transient
ligation of the ophthalmic vessels in rats [73]. In our
study, we describe significant decreases in areas of
myelination as well as loss of pre- and post-synaptic
proteins only in the contralateral hemisphere of the SC.
Several studies have shown the neuroprotective action
of JNK inhibitors, including SP600125 in the hippocam-
pus [69, 70]. However, we believe this to be the first
report of protection in the SC, or any visual center in
the brain, provided by JNK inhibition. Long-term ad-
ministration of SP600125 efficaciously preserved mye-
lination in the superficial SC as well as maintained
expression of an RGC pre-synaptic marker. In addition,
JNK inhibition may promote subsequent preservation
of structural integrity of post-synapses, which is necessary
for active neurotransmission and neurotrophic factor ex-
change. The same trend was observed with only 7 days of
dosing.
Conclusions
In summary, we have shown JNK inhibitors protected
RGCs against glutamate and TFW-induced cytotoxicity
in primary cultured retinal neurons. Further, intraperito-
neal injection of the JNK inhibitor SP600125 ameliorated
retinal I/R-induced degeneration and functional loss of
the inner neural retina and synaptic loss at RGC axon
terminals in the SC. Our findings implicate that JNK
activation, within hours immediately following reperfu-
sion, plays a pivotal role in cell death and pathological
progression in the retina and SC. This may be the crit-
ical therapeutic window for JNK inhibitors, at least in
this acute model of retinal I/R injury. Together with
previously published results, we suggest that the JNK
signaling pathway is a prominent and critical path for
neurodegeneration. Inhibition of this pathway represents
a promising novel therapeutic target for preventing neu-
rodegeneration in the visual axis related to retinal ische-
mic injury.
(See figure on previous page.)
Fig. 9 SP600125 ameliorated the I/R-induced reductions in ERG b-wave amplitudes. The a- and b- wave amplitudes of scotopic ERG at 10 cd light
intensity were measured in the vehicle and SP600125-treated groups 3, 7, 14, 21, and 28 days after I/R. Data represent mean ± SEM (n = 5). I/R in-
jury induced slight reductions of a-wave amplitudes (a) and significant (p < 0.05) impairment of b waves (b) over 28 days in the vehicle group. In
contrast, daily administration of SP600125 prevented impairment of a-waves and b-waves (a and b). Two-way ANOVA analyses
indicate that there were no significant time-dependent changes in all SP600125 groups, but significant differences were detected between the
control and I/R groups at certain time points (*: p < 0.05 by Bonferroni’s post-hoc test)
Fig. 10 SP600125 protected retinal I/R-induced reduction in size of superior colliculus. Regions of mouse brains containing SC from vehicle or
SP600125 (5, 15, 30 mg/kg)- treated groups after 28 days post retinal I/R injury were collected for serial frozen sectioning and black gold staining.
Bright field images were taken and cross-sectional area of superficial layers from each contralateral or ipsilateral side were measured and averaged
in series of all stained sections. In vehicle treated groups, I/R injury induced significant area volume loss (~16 %) in the contralateral SC region
compared to the ipsilateral region. However, SP600125 administration protected SC from I/R-induced area volume loss in contralateral
hemispheres. Data represent mean ± SEM (n = 4–5). The ipsilalateral area volume in each brain was set as a 100 %. *: p < 0.05 between
contralateral and ipsilateral volumes of SC by two-tailed, paired t-test
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Methods
Animal
Female Sprague–Dawley rats (2–4 months of age) from
Charles River Laboratories (Wilmington, MA) were used
for retinal cell culture. Female C57BL/6J mice (10–12
weeks of age) from the Jackson Laboratory (Bar Harbor,
ME) were used for transient retinal I/R studies. Animals
were maintained in 12-h:12-h/light:dark cycle. All stud-
ies and animal care were performed as approved by the
Institutional Animal Care and Use Committee at the
University of North Texas Health Science Center and
followed the Association for Research in Vision and
Ophthalmology (ARVO) Statement for the Use of Ani-
mals in Ophthalmic and Vision Research.
Mixed retinal cell culture
Culture of retinal neurons was performed as previously
reported [30]. Briefly, rats were euthanized by CO2 as-
phyxiation and their eyes enucleated. The retina from
each eye was dissected and incubated in a papain solution,
containing 2 mg/mL papain (Sigma, St. Louis, MO),
0.4 mg/mL DL-cysteine (Sigma), and 0.4 mg/mL bovine
serum albumin (Sigma) in Neurobasal medium (Gibco/
Invitrogen, Carlsbad, CA), for 25 min at 37 °C, then
washed 3 times with RGC culture medium (Neurobasal/
B27 medium containing 100 units/mL penicillin (Sigma),
100 μg/mL streptomycin (Sigma), 1 mM pyruvate (Gibco/
Invitrogen), 2 mM glutamine (Gibco/Invitrogen), 5 μg/mL
insulin (Sigma), 100 μg/mL transferrin (Sigma), 100 μg/
mL bovine serum albumin (Sigma), 60 ng/mL progester-
one (Sigma), 16 μg/mL putrescine (Sigma), 40 ng/mL
sodium selenite (Sigma), 40 ng/mL thyroxine (Sigma),
40 ng/mL tri-iodothyronine (Sigma), 50 ng/mL brain-
derived neurotrophic factor (BDNF; Biosource, Camarillo,
CA), 10 ng/mL ciliary neurotrophic factor (CNTF; Bio-
source), 10 ng/mL basic fibroblast growth factor (bFGF;
Biosource), 5 μM forskolin (Sigma), and 1 % fetal calf
serum (Atlas Biologicals, Fort Collins, CO)). Retinal pieces
were triturated by passing through a fire-polished dispos-
able glass pipette until cells were dispersed. Cell density
in the suspension was assessed with a Coulter counter
(Beckman Coulter, Fullerton, CA). 1 × 106 to 3 × 106
Fig. 11 SP600125 prevented I/R-induced impaired expression of synaptic markers VGLUT2 and PSD95 in the superior colliculus. Mouse brains
from vehicle or SP600125 (15 mg/kg) treatment groups were collected for immunohistochemistry at 28 days post retinal I/R injury. Each brain
section was incubated with primary antibody for presynaptic marker VGLUT2 or post-synaptic marker PSD95. a and c Images including both ipsi-
lateral (Ipsil) and contralateral (Cont) superficial layers of the superior colliculus from vehicle treated (above) and SP600125 treated (below) mice. b
and d Data represent mean ± SEM (n = 4 - 5). I/R injury resulted in significant fluorescence intensity loss of VGLUT2 (84.4 ± 19.0 %) and PSD95
(76.8 ± 12.6 %) in the contralateral SC after 28 days in vehicle-administered group (b and d). In contrast, 28-day administration of SP600125 pre-
vented the loss of both synaptic markers (b and d). Total area volume of the ipsilateral SC defines 100 %. *: p < 0.05 between contralateral and ip-
silateral volumes by two-tailed, paired Student’s t-test
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cells/well were placed onto poly-D-lysine- and laminin-
coated 8-well chambered culture slides (surface area =
0.69 cm2/well; Becton Dickinson, Franklin Lakes, NJ)
and cultured in 95 % air/5 % CO2 at 37 °C. These cell
cultures contained RGC-enriched retinal neurons [30].
More than 90 % of the cells were neurons, which were
positively labeled with neuron-specific enolase antibody.
Approximately 20–30 % of these cells expressed RGC
markers, Thy-1 and neurofilament-L. Morphologically,
the Thy-1-positive cells had the characteristic appear-
ance of neurons. After 2–3 days in culture, neurite out-
growth typically had 2–4 main branches of approximately
20–50 μm in length. Cells in culture were negative for
arrestin (photoreceptor), glial fibrillary acidic protein
(astroglia and Müller cell), glutamine synthetase (Müller
cell), or ED1 (microglia). Less than 10 % of the cells were
labeled with the protein kinase Cα antibody (rod bipolar
cells) [30]. Characterization of this cell culture system is
shown in Additional file 1: Table S1 and Figures S1–S8.
For glutamate-induced toxicity studies, cells were pre-
treated with vehicle or the indicated JNK inhibitors,
SP600125 (Sigma) or TAT-JNK-III, a cell-permeable pep-
tide inhibitor specific for JNK [76] (EMD Chemicals,
Billerica, MA), for 30 min, followed by 100 μM glutamate
(Sigma) for three days. For TNFα-induced toxicity studies,
cells were pre-treated with vehicle or the indicated com-
pounds for 30 min, followed by 10 ng/mL TNFα (Sigma)
for three days. For trophic factor withdrawal (TFW) stud-
ies, three trophic factors, bFGF, BDNF, and CNTF, were
removed from the culture medium. Cells were cultured in
this medium with the indicated compounds for three days.
At the end of the incubation period, the cells were fixed
Fig. 12 Seven-day administration of SP600125 also protected the retina from I/R-induced layer degeneration. SP600125 (15 mg/kg) was
administered to retinal I/R injured mice for the first 7 days only. SD-OCT scanning was used to determine progressive changes in whole retinal
layer (from NFL to ONL) or each sublayer including IPL, INL and ONL. Images were selected to show layer changes 28 days post I/R injury (a). Pro-
gressive changes of whole retinal layer or sub-layers were monitored (b). 7-day administration of SP600125 resulted in protection from retinal
layer degeneration induced by I/R injury after 28 day. Open symbols: I/R eyes; closed symbols: un-injured contralateral eyes. Two-way ANOVA ana-
lyses indicate that there were no significant time-dependent or injury-dependent changes. (WRL: whole retina layer, IPL: inner plexiform layer, INL:
inner nuclear layer, ONL: outer nuclear layer)
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and labeled for Thy-1, a RGC marker, by immunocyto-
chemistry (primary antibody against Thy-1, diluted 1:500;
Chemicon, Temecula, CA; secondary antibody: Alexa
fluor 594-labeled goat anti-mouse IgG, 1:300; Invitrogen/
Molecular Probes, Carlsbad, CA). Cell survival was quan-
tified by counting the Thy-1-positive cells in each well.
Retinal I/R and SP600125 administration
Retinal I/R was induced as described previously [27].
Briefly, mice were anesthetized with a ketamine/xylazine/
acepromazine cocktail (100/10/3 mg/kg) followed by can-
nulation of the anterior chamber with a 30 gauge needle
connected to a reservoir containing sterile PBS. The reser-
voir was elevated to generate an intraocular pressure of
120 mmHg for 1 h to induce retinal ischemia. The JNK
inhibitor SP600125 (5, 15, 30 mg/kg, 100 μL) or vehicle
control (6 % DMSO in PBS, 100 μL) was intraperitoneally
administered 2 h prior to retinal I/R, followed by once
daily injection after I/R.
Western blotting of retinal proteins
Whole retina was gently removed at indicated time
points after I/R injury and homogenized in mammalian
protein extraction reagent (MPER, Thermo Fisher Scien-
tific Inc, Rockford, IL). Total protein was quantified using
DC™ Protein Assay (Bio-RAD, Life Science Research,
Hercules, CA). Total retinal protein (50 μg) in Laemmli
buffer (Bio-RAD) and 0.5 % β-mercaptoethanol was elec-
trophoresed in 10 % SDS-PAGE gels. Gels were trans-
ferred to Immobilon-P PVDF transfer membrane (EMD
Millipore, Billerica, MA) followed by blocking in 10 %
non-fat milk. Membranes were incubated overnight in
4 °C with primary antibodies for pJNK (#9251), total
JNK (#9252), phospho-c-Jun (pc-Jun) (#2631), total c-
Jun (#9165), and GAPDH (#2118) from Cell Signaling
Technology (Danvers, MA), followed by incubation
with secondary antibody conjugated with horse radish
peroxidase (Cell Signaling Technology) for 1 h at room
temperature. Protein expression was detected using Super-
Signal West Femto Chemiluminescent substrate (Thermo
Fisher Scientific, Rockford, IL) and Alpha Innotech Gel
Documentation System with Flourchem 8900 software
(ProteinSimple, Alpha Innotech, Santa Clara, CA). Immu-
noblots were quantified using the ImageJ program (Na-
tional Institutes of Health, Bethesda, MD) and expression
was normalized to GAPDH.
Immunohistochemistry of retina
Ischemic or contralateral control eyes were gently re-
moved from euthanized mice and placed in 4 % para-
formaldehyde/PBS for 2 h followed by 20 % sucrose
embedding. Eyes were placed in Tissue-Tek O.C.T
Fig. 13 The 7-day administration of SP600125 protected I/R-induced reduction in VGLUT2 and PSD95 expression in the superior colliculus. (a) Mouse
brains from 7-day SP600125 treatment (15 mg/kg) were collected for immunohistochemistry 28 days post retinal I/R injury. (b) Data represent mean ±
SEM (n = 4) of percentages at each hemisphere from both contralateral (dark bars) and ipsilateral (open bars) sides compared to vehicle ipsilalateral
volume, set as a 100 %. No significant difference was detected between contralateral and ipsilateral samples by two-tailed, paired Student’s t-test
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compound (Sakura Finetek USA, Torrance, CA) and
stored at −80 °C. Eyes were frozen-sectioned at 10 μm
thickness and placed on Superfrost Plus Microscope Slides
(Fisher Scientific, Hampton, NH). Slides were washed
twice in PBS, blocked and permeabilized for 1 h using
blocking buffer (PBS with 10 % horse serum and 0.1 %
Triton X-100), then incubated with antibodies against
pJNK (#4668), pc-Jun (#3270) (Cell Signaling Technology,
Danvers, MA), and/or Tublin βIII (Tuj1 #801201, Biole-
gend, San Diego, CA), or PKCα (ab11723), Syntaxin
(ab112198) (Abcam plc. Cambridge, MA) for 16 h at 4 °C,
followed by treatment of secondary antibody conjugated
with Alexaflour 488 and Alexaflour 568 (Invitrogen) for
1 h at room temperature. Slides were mounted with cover
slips using ProlongGold anti-fade reagent with DAPI (Mo-
lecular Probes, Life Technologies, Grand Island, NY). All
retinal images were taken using Zeiss LSM Meta Confocal
microscope system (located in Johns Hopkins University,
School of Medicine, Baltimore, MD) and Zen 2009 soft-
ware (ZEISS, Thornwood, NY).
Histology of retina
Retinal layer thickness and cell numbers in ganglion cell
layer (GCL) were assessed as previously described [27].
Briefly, thicknesses of individual layers or whole retina
(from nerve fiber layer (NFL) to outer nuclear layer
(ONL), excluding outer segments) were measured using
the ImageJ program (NIH) at every quarter point of each
entire retinal cross-section (from ora serrata to ora ser-
rata) and averaged. Four retinal cross-sections were used
per eye and their results averaged. Cell numbers in GCL
were counted from each of the four cross-sections from
each eye and averaged.
Spectral domain optical coherence tomography (SD-OCT)
The SD-OCT ophthalmic Imaging System (Bioptigen,
Durham, NC) was used for retinal scanning. Mice were
anesthetized using a ketamine/xylazine cocktail (100/
10 mg/kg) and placed on a mouse holder. Using InVivo-
Vue software (Bioptigen), each retina was scanned with
rectangular scanning mode (1.2 × 1.2 mm) consisting of
1000 A scans per B scan × 100 B scans. Images from
superior, central, and inferior regions were analyzed
using ImageJ software with four measurements at quarter
points for thicknesses of the whole retinal layer, inner
plexiform layer (IPL), inner nuclear layer (INL), and ONL.
Scotopic electroretinography (ERG)
After 16 h of dark adaptation, mice were anesthetized
with isoflurane and connected to the HMsERG system
(Ocuscience, Rolla, MO) with body temperature con-
trolled at 37 °C. The study eye was exposed to a series of
light flashes of various intensities (0.1, 0.3, 1, 3, 10, and
25 cd/m2). Amplitudes and implicit times of ERG wave-
forms were measured and analyzed.
Brain histology and immunohistochemistry
For black gold staining, blocks of mice brains bracketing
the SC (3 mm to 6 mm caudal to bregma) were frozen-
sectioned at 40 μm thickness and placed on slides. Slides
were incubated with 0.3 % Black Gold II solution (Histo-
Chem, Jefferson, AR) at 60 °C as instructed by the manu-
facturer. Before mounting, slides were washed in PBS and
dehydrated in a series of 95 % ethanol (2 min), 100 % etha-
nol (2 min) and xylene (2 min). All bright-field images
were taken using Nikon eclipse Ti inverted microscope
and CRi Nuance FX multispectral imaging system with
Nuance 3.0 software. Cross-sectional areas of SC of all
slides were measured from the myelinated SC layer III to
superficial layer in each hemisphere as previously de-
scribed [77] using the ImageJ polygonal selection method.
The cross-sectional areas of SC of all slides from each
hemisphere of the same brain were averaged and reported.
For immunohistochemistry, brains were frozen-sectioned
at 10 μm thickness. Prior to applying primary antibody,
slides were hydrated in PBS for 10 min and blocked with
10 % goat serum containing 0.1 % Triton X-100 in
PBS. Anti-VGLUT2 (ab79157, Abcam) and anti-PSD95
(ab18258, Abcam) antibodies were applied at 4 °C over-
night. Slides were washed and incubated with secondary
antibodies conjugated with Alexaflour 488 or Alexaflour
568 for 1 h at room temperature. All fluorescence images
were taken using the same system described above. Im-
ages were taken using Nikon eclipse Ti inverted micro-
scope (Nikon) and CRi Nuance FX multispectral imaging
system (Caliper Life Sciences, Hopkinton, MA). All back-
ground autofluorescence was subtracted using Nuance 3.0
software (Caliper Life Sciences).
Statistics
Statistical analysis was performed using GraphPad Prism
Version 5.0 (GraphPad Software, San Diego, CA). Student’s
t-test was used to compare two experimental groups. One-
way or two-way ANOVA was used to compare among
three or more groups. The specific statistical method used
is described in the respective figure legends. All data are
expressed as means ± standard error of mean (SEM). A
p value less than 0.05 is considered statistically significant.
Additional file
Additional file 1: Table S1. Summary of distribution of cell markers in
the mixed rat retinal cell culture. Figure S1. Representative images showing
colocalization of Thy-1 and neurofilament-L (NF-L) by immunocytochemistry
in cultured rat retinal cells. Figure S2. Representative images showing lack
of colocalization of Thy-1 and arrestin by immunocytochemistry in cultured
rat retinal cells. There were no arrestin positive cells in culture. Figure S3.
Representative images showing lack of colocalization of Thy-1 and ED-1
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(CD68) by immunocytochemistry in cultured rat retinal cells. There were no
ED-1 positive cells in culture. Figure S4. Representative images show-
ing lack of colocalization of Thy-1 and glutamine synthetase (GS) by im-
munocytochemistry in cultured rat retinal cells. There were no GS
positive cells in culture. Figure S5. Representative images showing lack
of colocalization of Thy-1 and GFAP by immunocytochemistry in
cultured rat retinal cells. There were no GFAP positive cells in culture.
The lower right-hand panel includes brain astrocytes as a positive
control for the anti-GFAP antibody. Figure S6. Representative images
showing lack of colocalization of Thy-1 and PKCα by immunocytochemistry
in cultured rat retinal cells. There were very few PKCα positive cells in
culture. Figure S7. Representative images showing partial colocalization of
Thy-1 and neuron-specific enolase (NSE) by immunocytochemistry in
cultured rat retinal cells. Figure S8. Effect of glutamate on RGC morphology.
Cells were treated with glutamate (100 μM) or vehicle for 3 days. (Top
panels) The cells were labeled with anti-Thy-1 antibody (red) and DAPI
nuclear stain (blue). (Bottom panels) The corresponding phase-contrast
image. Figure S9. Retinal c-Jun phosphorylated c-Jun was attenuated by
SP600125 administration in 24 h after I/R injury. Phosphorylated c-Jun was
detected (green fluorescence). Tuj-1 immunofluorescence (red) was used as
RGC marker. DAPI staining (blue) represents cell nuclei for counter staining.
(A) Vehicle, (B) SP600125. (PDF 362 kb)
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